What is the 13F Pro Quality Score for SER?

13F Pro ranks Serina Therapeutics, Inc. (SER) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SER's current score at https://13fpro.ai/company/SER (free sign-up required for the full ranking).

Where does 13F Pro source SER data?

All Serina Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Serina Therapeutics, Inc. files with the SEC under CIK 1708599. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SER in?

Serina Therapeutics, Inc. (SER) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SER research updated on 13F Pro?

SER's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Serina Therapeutics, Inc.(SER)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1708599 SER stock profile & AI dashboard →

13F Pro Quality Score

8.7/100

Rank #2,924 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SER Scores 9/100

exact factor attribution · 2026-09-11

SER's composite is held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-2.2 pts

7th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.4 pts

1th pct

Earnings quality

-3.8 pts

12th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.7 pts

3th pct

Profitability

-7.3 pts

1th pct

Free cash flow

-7.4 pts

1th pct

Scale

-7.4 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SER Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Serina Therapeutics, Inc. (SER), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SER at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,924 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Serina Therapeutics, Inc. reports net income of $-6.4M, free cash flow of $-6.7M. Top institutional holders of SER by reported 13-F value include Sio Capital Management, VANGUARD CAPITAL MANAGEMENT, Waverly Advisors, based on the most recent SEC filings. SER trades on the NYSE exchange and files with the SEC under CIK 1708599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SER daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Serina Therapeutics, Inc. directly from SEC EDGAR. Serina Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 9 and 27 since 2026, currently 8.7 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-6.4M

Free Cash Flow

Q2 2026

$-6.7M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+132.1% YoY

$130.0KFY 2025

FY22 $34.0KFY23 $3.2MFY24 $56.0KFY25 $130.0K

Net Income

-72.2% YoY

$-19.2MFY 2025

FY22 $-10.5MFY23 $5.3MFY24 $-11.1MFY25 $-19.2M

Operating Income

-40.9% YoY

$-24.0MFY 2025

FY22 $-7.0MFY23 $-3.1MFY24 $-17.0MFY25 $-24.0M

EPS (Diluted)

-26.5% YoY

$-1.91FY 2025

FY22 $-9.70FY23 $0.73FY24 $-1.51FY25 $-1.91

Total Assets

+3.4% YoY

$7.0MFY 2025

FY22 $3.2MFY23 $9.0MFY24 $6.7MFY25 $7.0M

Total Debt

—FY 2025

FY22 $18.1MFY23 —FY24 —FY25 —

Op. Cash Flow

-4.8% YoY

$-18.0MFY 2025

FY22 $-5.9MFY23 $-2.5MFY24 $-17.1MFY25 $-18.0M

Free Cash Flow

-5.0% YoY

$-18.0MFY 2025

FY22 —FY23 $-3.0MFY24 $-17.2MFY25 $-18.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$130.0K +132.1%	$56.0K -98.2%	$3.2M +9173.5%	$34.0K -76.4%	$144.0K -60.1%	$361.0K
Net Income	$-19.2M -72.2%	$-11.1M -311.4%	$5.3M +150.4%	$-10.5M -20.6%	$-8.7M +20.2%	$-10.9M
Operating Income	$-24.0M -40.9%	$-17.0M -444.8%	$-3.1M +55.1%	$-7.0M +12.1%	$-7.9M +21.5%	$-10.1M
EPS (Diluted)	$-1.91 -26.5%	$-1.51 -306.8%	$0.73 +107.5%	$-9.70	—	—
Total Assets	$7.0M +3.4%	$6.7M -25.0%	$9.0M +176.7%	$3.2M +2.8%	$3.2M -19.6%	$3.9M
Total Debt	—	—	—	$18.1M +37.3%	$13.2M	—
Operating Cash Flow	$-18.0M -4.8%	$-17.1M -592.1%	$-2.5M +58.3%	$-5.9M +24.4%	$-7.9M -0.5%	$-7.8M
Free Cash Flow	$-18.0M -5.0%	$-17.2M -475.8%	$-3.0M	—	—	$-7.8M

Get alerted when SER's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Serina Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SER

Sio Capital Management, LLC
$1.9M1,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$314.7K162,198 sh
Waverly Advisors, LLC
$130.9K67,492 sh
GEODE CAPITAL MANAGEMENT, LLC
$99.0K51,007 sh
Keel Point, LLC
$41.7K21,508 sh
NORTHERN TRUST CORP
$40.3K20,771 sh
VANGUARD FIDUCIARY TRUST CO
$38.8K20,009 sh
Avidian Wealth Solutions, LLC
$36.5K18,800 sh
JANE STREET GROUP, LLC
$30.0K15,444 sh
STATE STREET CORP
$24.8K12,758 sh

Fund	Value	Shares
Sio Capital Management, LLC	$1.9M	1,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$314.7K	162,198
Waverly Advisors, LLC	$130.9K	67,492
GEODE CAPITAL MANAGEMENT, LLC	$99.0K	51,007
Keel Point, LLC	$41.7K	21,508
NORTHERN TRUST CORP	$40.3K	20,771
VANGUARD FIDUCIARY TRUST CO	$38.8K	20,009
Avidian Wealth Solutions, LLC	$36.5K	18,800
JANE STREET GROUP, LLC	$30.0K	15,444
STATE STREET CORP	$24.8K	12,758

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SER on your watchlist

Track score changes the day Serina Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SER a good stock to buy?

13F Pro's AI-powered analysis of Serina Therapeutics, Inc. (SER) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SER are available on the SER stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SER is classified as a small company.

Which hedge funds own SER?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SER. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Serina Therapeutics, Inc.'s investment landscape.